Table 1 Demographics, clinical characteristics, and laboratory data of the study cohort
HIV-positive (n = 28) | HIV-negative (n = 25) | p-value | |
|---|---|---|---|
Demographics | |||
Age at death (years) | 56.1 (8.9) | 64.9 (15.1) | 0.001 |
Gender (male) | 23 (82.0) | 11 (44.0) | 0.006 |
Race (Caucasian) | 23 (42.9) | 13 (52.0) | 0.5 |
Post-mortem interval (hours) | 13.5 (16.4) | 24 (40.5) | 0.03 |
Substance use and comorbidities | |||
Smoking | 16 (57.1) | 10 (40.0) | 0.2 |
Illicit drugs | 18 (64.3) | 0 (0.0) | <0.00001 |
Alcohol | 11 (39.3) | 0 (0.0) | 0.0004 |
HCV or HBV infection | 15 (46.0) | 2 (8.0) | 0.002 |
BMI | 22.9 ± 3.8 | 26.8 ± 6.0 | 0.05 |
Hypertension | 17 (60.7) | 16 (64.0) | 0.8 |
Diabetes | 4 (14.3) | 5 (20.0) | 0.6 |
Hyperlipidemia | 19 (67.9) | 17 (68.0) | 0.99 |
Cancer | 13 (46.4) | 5 (20.0) | 0.04 |
Cardiovascular disease | 12 (42.9) | 18 (72.0) | 0.03 |
Cerebrovascular disease | 12 (42.9) | 10 (40.0) | 0.99 |
HAND | 9 (32.1) | - | - |
Laboratory values | |||
Creatinine (mg/dL) | 2.1 ± 1.7 | 1.9 ± 1.2 | 0.7 |
ALT (U/L) | 57.8 ± 63.3 | 70.5 ± 122.1 | 0.7 |
AST (U/L) | 80.5 ± 112.0 | 108.5 ± 140.1 | 0.5 |
ALP (U/L) | 131.2 ± 201.0 | 98.1 ± 47.2 | 0.2 |
Total bilirubin (mg/dL) | 4.4 ± 9.8 | 1.8 + 4.4 | 0.3 |
Total cholesterol (mg/dL) | 183.9 ± 79.8 | 185.5 ± 44.9 | 0.9 |
LDL (mg/dL) | 78.9 ± 30.5 | 107.2 ± 43.3 | 0.09 |
HDL (mg/dL) | 40.3 ± 16.6 | 49.7 ± 16.1 | 0.2 |
Triglycerides (mg/dL) | 172.7 ± 62.3 | 170.6 ± 86.8 | 0.9 |
HgA1c (%) | 5.1 ± 0.7 | 6.3 ± 1.6 | 0.04 |
APOE genotype (E4) | 3 (14.3) | ND | - |
HIV-related characteristics | |||
CD4 count (cells/μL) | 214.7 ± 161.1 | - | - |
CD4 count <200 cells/μL | 14 (50.0) | ||
Plasma viral load (copies/mL) | 295 (1307) | - | - |
Plasma viral load <400 copies/mL | 22 (81.5) | ||
CSF viral load <40 copies/mL | 7 (87.5) | - | - |
On HAART | 25 (89.3) | - | - |
AIDS-related causes of death | 10 (35.7) | - | - |